

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Review

- 887** EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders
J JW Kuiper, J C Prinz, E Stratikos, P Kuśnierczyk, A Arakawa, S Springer, D Mintoff, I Padjen, R Shummalieva, S Vural, I Köter, M G van de Sande, A Boyvat, J H de Boer, G Bertias, N de Vries, C LM Kriekaert, I Leal, N Vidovič Valentinčič, I Tugal-Tutkun, H el Khaldi Ahanach, F Costantino, S Glatigny, D Mrazovac Zimak, F Lötscher, F G Kerstens, M Bakula, E Viera Sousa, P Böhm, K Bosman, T J Kenna, S J Powis, M Brehan, A Gul, J Bowes, R JU Lories, J Nowatzky, G J Wolbink, D G McGonagle, F Turkstra, EULAR studygroup
MHC-I-opathies

Viewpoint

- 897** What is a response in randomised controlled trials in giant cell arteritis?
C Dejaco, S Ramiro, Z Touma, M Bond, M Soowamber, C Sanchez-Alvarez, C A Langford

Rheumatoid arthritis

- 901** Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
L E Kristensen, S Danese, A Yndestad, C Wang, E Nagy, I Modesto, J Rivas, B Benda

Inflammatory arthritis

- 911** Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
V Huss, H Bower, K Hellgren, T Frisell, J Askeling, Behalf of the ARTIS group
- 920** Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
A R Bass, N Abdel-Wahab, P D Reid, J A Sparks, C Calabrese, D P Jannat-Khah, N Ghosh, D Rajesh, C A Aude, L Gediminas, L MacFarlane, S Arabelovic, A Falohun, K Mushtaq, F A Haj, A Diab, A A Shah, C O Bingham, K K Chan, L C Cappelli

Systemic lupus erythematosus

- 927** Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes
M Y Choi, I Chen, A E Clarke, M J Fritzler, K A Buhler, M Urowitz, J Hanly, Y St-Pierre, C Gordon, S-C Bae, J Romero-Diaz, J Sanchez-Guerrero, S Bernatsky, D J Wallace, D A Isenberg, A Rahman, J T Merrill, P R Fortin, D D Gladman, I N Bruce, M Petri, E M Ginzler, M A Dooley, R Ramsey-Goldman, S Manzi, A Jönsen, G S Alarcón, R F van Vollenhoven, C Aranow, M Mackay, G Ruiz-Irastorza, S Lim, M Inanc, K Kalumian, S Jacobsen, C Peschken, D L Kamen, A Askana, J P Buyon, D Sontag, K H Costenbader

Vasculitis

- 937** Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
R M Smith, R B Jones, U Specks, S Bond, M Nodale, R Al-jayyousi, J Andrews, A Bruchfeld, B Camilleri, S Carette, C K Cheung, V Derebail, T Doulton, A Ferraro, L Forbess, S Fujimoto, S Furuta, O Gewurz-Singer, L Harper, T Ito-Ihara, N Khalidi, R Klocke, C Koenig, Y Komagata, C Langford, P Lanyon, R Luqmani, C McAlear, L W Moreland, K Mynard, P Nachman, C Pagnoux, C A Peh, C Pusey, D Ranganathan, R L Rhee, R Spiera, A G Steih, V Tesar, G Walters, C Wroe, D Jayne, P A Merkel, RITAZAREM co-investigators

Autoimmunity

- 945** Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity
N Oskam, P Ooijevaar-De Heer, D Kos, J Jeremiasse, L van Boheemen, G M Verstappen, F G M Kroese, D van Schaardenburg, G Wolbink, T Rispens

MORE CONTENTS ►



EDITOR'S CHOICE



OPEN ACCESS

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

Epidemiology

- 957** Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
Z S Wallace, G Miles, E Smolkeina, N Petruski-Ivleva, D Madziva, C Cook, X Fu, Y Zhang, J H Stone, H K Choi

Osteoarthritis

- 963** Inhibition of KDM7A/B histone demethylases restores H3K79 methylation and protects against osteoarthritis
R Assi, C Cherifi, F M.F Cornelis, Q Zhou, L Storms, S Pazmino, R Coutinho de Almeida, I Meulenbelt, R J Lories, S Monteagudo

- 974** A meta-analysis and a functional study support the influence of mtDNA variant m.16519C on the risk of rapid progression of knee osteoarthritis
A Durán-Sotuelo, M Fernández-Moreno, V Suárez-Ulloa, J Vázquez-García, S Relación, T Hermida-Gómez, V Balboa-Barreiro, L Lourido-Salas, V Calamia, P Fernández-Puente, C Ruiz-Romero, J Fernández-Tajes, C Vaamonde-García, M C de Andrés, N Oreiro, F J Blanco, I Rego-Perez

Osteoporosis

- 985** Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy
N Alonso, O M E Albagha, A Azfer, B Larráz-Prieto, K Berg, P L Riches, B Ostaneck, T Kocjan, J Marc, B L Langdahl, S H Ralston

Images in rheumatology

- 992** Clinical image: synovitis of the metacarpophalangeal joints
L van der Weele, T Niessink, M Maas, P Don Griot, M Janssen, C Otto, T L Jansen, S W Tas, N de Vries

Letters

- 994** Baricitinib for juvenile idiopathic arthritis: a monocentric case series
I Maccora, T Oliverio, I Pagnini, E Marrani, M V Mastrolia, G Simonini
- 995** Complete resolution of gastric antral vascular ectasia after autologous haematopoietic stem cell transplantation in systemic sclerosis
S Keret, T Zuckerman, I Henig, T Rainis, S Odeh, N Artoul, A Shouval, G Slobodin, D Rimar
- 996** COVID-19 infection after autologous stem cell transplantation for systemic sclerosis
J C Henes, I Martac, W Vogel, C Lengerke, R Klein, L Hensen, A-C Pecher

Electronic pages

- e153** Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'
T Klopfenstein, V Gendrin, T Conrozier, A Gerazime, M Puyraveau, S Zayet
- e154** Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein *et al*
R BM Landewé, S Ramiro, R L M Mostard
- e155** Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey'
F Montero, I Castrejón, J Martínez-Barrio, J C Nieto-González, J Rivera, J M Álvaro-Gracia, J Molina Collada
- e156** Response to 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey'' by Montero *et al*
A Tomelleri, L Dagna, C Campochiario
- e157** Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks *et al*
E Gremese, G Ferraccioli
- e158** Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks *et al*
Z S Wallace, J A Sparks, P C Robinson, P M Machado, J Yazdany
- e159** Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M *et al*. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients
F Cacciapaglia, A Manfredi, G Erre, M Piga, G Sakellariou, ombretta viapiana, E Gremese, F R Spinelli, F Atzeni, E Bartoloni

- e160** Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'
Q A Dumoulin, X M E Matthijssen, F Wouters, D I Krijbolder, E Niemantsverdriet, A H M van der Helm-van Mil
- e161** Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin *et al*
I Gessl, D Aletaha, P Mandl
- e162** Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'
S Jain, V Dhir
- e163** Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir *et al*
V Stouten, R Westhovens, S Pazmino, D De Cock, K Van der Elst, J Joly, D Bertrand, P Verschueren
- e164** Correspondence on 'Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial'
D G McGonagle, C Bridgewood, H Marzo-Ortega
- e165** Response to: 'Correspondence on 'Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial'' by McGonagle *et al*
M S Kragsnaes, J Kjeldsen, H C Horn, H L Munk, J K Pedersen, S A Just, P Ahlquist, J R Davidsen, A C Nilsson, R Röttger, M Kruhöffer, J R Marchesi, K Kristiansen, R Christensen, T Ellingsen
- e166** Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'
G Cai, X Peng
- e167** Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng
A Molto, D van der Heijde, F E Van den Bosch, M Dougados
- e168** Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'
Y Zhao, J-X Huang
- e169** Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang
J C-C Wei, T-H Kim, M Kishimoto, N Ogusu, H Jeong, S Kobayashi
- e170** Correspondence on 'Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?'
C-L Su, J-W Chen, J C-C Wei
- e171** Response to: 'Correspondence on 'Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?' by Su *et al*
X Baraliakos, A Richter, C O Schmidt, J Braun
- e172** Correspondence on 'Warfarin use and risk of knee and hip replacements'
N He, Z Fang, X Li, S Zhai
- e173** Response to: 'Correspondence on: 'Warfarin use and risk of knee and hip replacements'' by He *et al*
P Ballal, C Peloquin, C G Boer, T Neogi
- e174** Correspondence on 'Variants in urate transporters, *ADH1B*, *GCKR* and *MEPE* genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank'
R Takei, N A Sumpter, A Phipps-Green, M Cadzow, R K Topless, R J Reynolds, T R Merriman
- e175** Response to: 'Correspondence on 'Variants in urate transporters, *ADH1B*, *GCKR* and *MEPE* genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank'' by Takei *et al*
G Sandoval-Plata, K Morgan, A Abhishek
- e176** Correspondence on 'classification criteria: time for a rethink' by D Porter *et al*
H Yazici, Y Yazici